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Abstract: In recent times there is an emerging evidence about the increased risk of cardiovascular disease (CVD) and 
rheumatic conditions. This review has been focused on the multiple relationships between rheumatoid arthritis (RA) and 
heart failure (HF) features.  
Cardiovascular (CV) system involvement is an extra-articular complication of RA and is a major cause of morbidity and 
mortality. All heart structures may be affected in RA and different clinical manifestations may be seen. 
HF is a complex clinical syndrome which represents universal end-stage of nearly every form of heart disease and has a 
poor prognosis. Patients with RA have almost 2-fold higher risk of HF development than non RA-subjects and this high 
risk is not explained entirely by traditional CV risk factors. RA patients with HF appear to have a more subtle 
presentation of HF, compared to HF patients without RA, while mortality from HF is significantly higher. In RA HF mostly 
is manifested by diastolic dysfunction (DD) which is revealed by echocardiography. In general, brain natriuretic peptide 
(BNP) is an important clinical and prognostic marker of HF, but there are no final data concerning its screening value in 
RA-subjects.  
Nevertheless, up to date HF is still being poorly revealed in most RA-patients, especially on early stages of the disease, 
which leads to HF treatment delay, thus contributing to mortality.  
These findings emphasize the role and need of further larger studies in this field, which will bring to early identification 
and treatment of RA-subjects with HF and a decrease in mortality rates. 
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INTRODUCTION 
In recent years there is a great attention towards the 
relationships between cardiovascular disease (CVD) 
and rheumatic diseases. The increased risk of CVD 
has been described extensively in rheumatoid arthritis 
(RA) [1-4], systemic lupus erythematosus (SLE) [5-7], 
ankylosing spondylitis (AS) and psoriatic arthritis [8-13]. 
RA is a systemic disease of unknown origin, which 
is characterized by chronic inflammatory process and 
mainly leading to small and large joints synovial 
membrane destruction. The prevalence of RA is 0.5-
1% in general population of adults and women at 
reproductive age are 2-3 times higher affected by the 
disease [14, 15]. RA is an invalidating disease which is 
associated with life quality changes and decrease in 
mean duration of life [16]. Furthermore, there is 
observed high incidence of early mortality after the 
onset of disease, which particularly can be explained 
by infective, digestive, renal or pulmonary 
complications and lung neoplasia (mainly lung cancer 
and non-Hodgkin lymphoma [17]. 
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Cardiovascular (CV) system involvement is an 
extra-articular complication of RA and is a major cause 
of morbidity and mortality. All heart structures may be 
affected by various pathogenic mechanisms and res- 
pectively different clinical manifestations may be seen: 
valvular heart disease, pulmonary hypertension, rhythm 
and conduction disturbances, myocarditis/pericarditis, 
myocardial fibrosis, coronary heart disease (CHD) up 
to myocardial infarction (MI), and particularly, heart 
failure (HF) [18].  
Moreover, RA is suggested to be an independent 
risk factor for CHD development similar to type 2 
diabetes mellitus (DM) [19]. 
HF in RA 
HF is a complex clinical syndrome which represents 
universal end-stage of nearly every form of heart 
disease and has a poor prognosis [20, 21].  
Patients with RA have almost 2-fold higher risk of 
HF development than those without RA and this high 
risk is not fully explained by traditional CV risk factors 
[22]. 
Furthermore, RA patients with HF appear to have a 
more subtle presentation of HF, compared to HF 
patients without RA, while mortality from HF is 
significantly higher [23]. 
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The increased risk of developing HF in RA is well 
described [24-26]. In particular, in a population-based 
incidence cohort of patients with RA over a 40-year 
period there was observed a higher incidence of HF 
among patients with RA compared with a cohort of 
non-RA patients. After adjusting for age, sex, CHD, and 
traditional CV risk factors, the risk of developing HF 
(defined by Framingham Heart Study Criteria) in 
patients with RA was almost twice that of non-RA 
patients (HR 1.87, 95% CI 1.47-2.39), with an increase 
in cumulative incidence observed over time. Though 
higher incidence of HF was seen among all age 
groups, it tended to be increased in women compared 
with men (relative risk [RR] 1.9, 95% CI 1.4-2.5 vs RR 
1.3 95% CI 0.9-2.0) [22]. 
Compared with the general population, HF in 
patients with RA seems to be more frequently 
associated with diastolic dysfunction (DD) [27, 28]. 
After adjusting for age, sex, and history of CHD, 
patients with RA were twice as likely to have preserved 
LV ejection fraction (EF) (odds ratio [OR] 1.90, 95% CI 
0.98-3.67) [29]. When HF with reduced EF does occur 
in patients with RA, it is seen much more frequently in 
men (HR 3.7, 95% CI 1.8-7.7) [25]. DD is a predictor 
for incident HF independent of the traditional CV risk 
factors (HR 1.81, 95% CI 1.01-3.48) [31, 33]. 
Echocardiographic findings of DD were associated with 
an increase in all-cause and cardiac mortality [32-34]. 
Risk Factors of CVD and RA 
Risk factors of HF range very widely from lifestyle 
factors to comorbidities, medications, laboratory and 
genomic markers, etc. [35-38]. However, the main risk 
factors include hypertension, CHD, diabetes mellitus, 
and obesity. Hypertension and CHD are the most 
common and strongest risk factors conferring a 2-3 
times increased risk [39]. HF risk increases with age 
and male gender is associated with a higher risk [40]. 
Valvular heart disease, low physical activity, obesity, 
coffee consumption, increased salt intake, and low 
socioeconomic status all have been associated with 
increased risk [40, 41]. Excessive alcohol intake 
increases BP, but light-to-moderate consumption 
lowers the risk of HF [42-44]. Smoking promotes 
several CVD risk factors associated with HF [40, 45]. 
Dyslipidaemia, renal dysfunction, some medications 
(e.g. chemotherapeutic agents) and comorbidities 
(anaemia, microalbuminuria, increased heart rate, etc.) 
are also associated HF [46-49]. 
Risk factors for RA include female sex, a positive 
family history, older age, silicate exposure, and 
smoking [50-52]. Consumption of more than 3 cups of 
coffee daily (particularly decaffeinated coffee) also may 
contribute to RA development [53].  
Thus, age, smoking and coffee consumption are the 
same risk factors for the development of both HF and 
RA. 
The increased risk of CVD in RA patients is not 
entirely explained by an increased incidence of the 
traditional CV risk factors. Some traditional risk factors 
in RA may even play a paradoxical role [24, 54, 55]. 
The influence of age on the CV risk in patients with 
RA may be even greater than for the general 
population. In a population-based inception cohort of 
patients with RA with no prior CVD history the effect of 
age on CVD risk was almost twice that in the general 
population in men and more than twice that in women. 
The impact of age on CVD risk in seronegative patients 
and in subjects younger than 50 years was similar to 
that seen in the general population [56]. 
The prevalence of smoking is higher in patients with 
RA, but this risk factor alone is unlikely to account for 
the increased CVD risk [55, 57, 58]. 
DM, arterial hypertension, dyslipidaemia, and 
alcohol use/abuse have not been described more 
frequently in patients with RA when compared with 
non-RA subjects [22-24, 58].
 
Obesity and lipids seem to play a paradoxical role in 
CVD risk in patients with RA, with a lower BMI and 
lower total cholesterol associated with higher CV risk 
[58, 59]. Patients with RA with a higher BMI have lower 
mortality rates than that seen in thinner patients 
independent of RA onset, age, duration, and smoking 
status [60]. 
HDL, LDL and total cholesterol levels may be 
reduced in patients with untreated RA and later 
increase with suppression of inflammation via 
treatment, although the increase in LDL cholesterol 
associated with RA treatment does not seem to confer 
a higher CV risk [61-63].  
Patients with RA tended to have a lower likelihood 
of achieving therapeutic LDL levels after statin use. 
Increased erythrocyte sedimentation rate (ESR) is 
associated with a lower likelihood of achieving LDL 
targets, which underscores the importance of disease 
activity control in risk factor modification [64]. 
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Close relationship between RA and CVD is mainly 
explained by the similarities in the inflammatory and 
immunologic responses [65].  
Chronic systemic inflammation can promote 
endothelial cell activation and vascular dysfunction, 
which leads to decreased blood vessel compliance and 
atheroma formation, i.e. systemic inflammation 
accelerates development of atherosclerosis and heart 
disease.  
The role of T lymphocytes is crucial in both RA and 
heart disease [66, 67]. HLA-DRB1, which is the major 
risk gene for RA, predisposes to RA by promoting the 
selection and survival of auto reactive CD4+ T cells. 
HLA-DRB1 alleles are also associated with increased 
risk of MI and various forms of non-RA-associated 
heart disease [68, 69]. As in heart disease, T 
lymphocytes isolated from the joints of RA-subjects 
have enhanced production of interferon-γ and 
interleukin-17, which presumably mediate chronic 
inflammation [70, 71]. 
Structural and Functional Changes of Myocardium 
in RA 
Patients with RA are more likely to have abnormal 
LV geometry (higher LV mass and LV hypertrophy) 
than healthy people without RA. These abnormalities 
are associated with an increased risk of CVD. There is 
a strong association between increased LV mass (seen 
in patients with RA) and incident HF (HR 1.4 per 10% 
increment, P<0.0001) [72, 73]. 
Patients with RA with abnormal LV geometry are 
also significantly more likely to have LV concentric 
remodelling (OR 4.73, 95% CI 2.85-7.83), which is 
associated with a higher risk of incident CHD [72, 74]. 
Speckle-tracking echocardiography is an advanced 
echocardiographic modality for detection of myocardial 
changes during contraction and relaxation (i.e., 
myocardial strain) [75, 76]. According to the results of a 
population-based study in 87 patients with RA speckle-
tracking echocardiography revealed a reduction in LV 
and right ventricular strain in RA patients when 
compared with the general population, which correlated 
with markers of disease severity [77]. 
Relationships between RA Characteristics, 
Duration and CVD 
The RA disease characteristics seem to have an 
impact both on the risk of CVD development and CV 
mortality, with rheumatoid factor (RF) positivity and 
disease severity conferring the greatest risk [78, 79]. 
Positive RF is a significant predictor of CV events 
including HF all-cause and CV mortality among the 
general population, suggesting a role for antibodies in 
the pathogenesis of CVD [79, 80]. Among RF-negative 
subjects, after adjusting for age, sex, CHD, and CV risk 
factors, the increased risk of HF was no longer 
significant in a population-based cohort study but 
remained significant with a 2.5-fold increased risk 
among RF-positive subjects (adjusted HR 2.59, 95% CI 
1.95-3.43) [22]. Severe extra-articular manifestations of 
disease are associated with a higher likelihood of 
developing HF (HR 3.1, 95% CI 1.9-5.1) even after 
adjustment for CV risk factors [25]. The presence of 
rheumatoid lung disease and RA vasculitis, as disease 
severity markers, has also been associated with a 
greater likelihood of CV death [78]. 
It seems that the increased CVD risk in RA may 
predate the clinical manifestations of the disease, with 
evidence of atherosclerosis and CHD predating the 
diagnosis [81]. After the RA diagnosis, the relationship 
between the disease duration and CVD outcomes is 
less clear. The risk of DD in RA patients may be 
associated with the duration of disease: in population-
based cohort studies there was shown that after 
adjusting for CV risk factors, there was a significant 
association between the duration of the disease and 
DD (OR 3.2, 95% CI 1.8-5.4) [82, 83].  
Clinical Manifestations of CVD in RA Patients 
It was shown that RA patients are less likely to have 
angina pectoris as a manifestation of CHD (OR 0.58, 
95% CI 0.34-0.99), more likely to have silent MI (OR 
5.86, 95% CI 1.29-26.64) compared with the general 
population, and less likely to have typical ECG changes 
at presentation [54, 84]. 
The difference in clinical presentation may contribute to 
delays in the recognition and treatment of patients with 
RA and emphasizes the importance of a high index of 
suspicion in these patients.  
Typical clinical features of HF are less likely to be 
evident at presentation in patients with RA. Studies 
showed that they are less likely to have dyspnea on 
exertion, orthopnea, or paroxysmal nocturnal dyspnea 
at presentation. Patients with RA in this study were 
also more likely to have rales compared with non-RA 
subjects and less likely to have elevated BP at 
presentation [23]. 
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The Role of Laboratory Markers: Brain Natriuretic 
Peptide (BNP) and Cardiac Troponin (cTn) 
BNP is an important and prognostic biomarker of 
HF which is released mainly in heart ventricles and 
atria as a result to an increase in volume or pressure in 
heart chambers. Herewith, it was shown that BNP 
release has no circadian rhythm [29]. 
In general population BNP is used as a screening 
tool for LV DD detection, i.e. it may reveal 
asymptomatic patients with HF [85, 86]. 
There is no definite approach for BNP use in HF 
during RA. Harney SMJ et al. showed that BNP may be 
a potential beneficial method for HF screening [87]. 
Nevertheless, there is a need in larger studies to 
confirm this observation. 
There is evidence that patients with no CVD history 
had higher BNP levels than healthy control subjects. 
Patients with active RA had higher levels of BNP than 
those with moderate or no activity, which suggests 
possibility of direct cardiodepressive effect of 
inflammatory cytokines [88]. 
In patients without clinical CVD, those with RA were 
more likely to have elevated BNP levels than non-RA 
subjects (16% vs 9%, P<0.001). Patients with RA with 
abnormal BNP are more likely to have LV DD 
compared with those with normal BNP, but the 
specificity compared with non-RA patients (89% vs 
94%, P=0.02) and the positive predictive value (25%) 
of elevated BNP in patients with RA is low (25%) and 
is, therefore, not a good screening tool [89]. The 
duration of RA and CRP levels is independently 
associated with N-terminal proBNP [90]. 
In RA patients without HF high sensitive cTn-I is 
elevated independently of CV risk profile and 
inflammatory markers, which may suggest subclinical, 
silent damage of myocardium in these patients [91]. 
Prognosis and Outcome 
The prognosis in RA patients with HF is worse than 
in those subjects without RA. In a community-based 
cohort study by Davis JM 3rd et al., the 30-day 
mortality rate following the onset of HF was higher for 
RA compared to non-RA subjects (at 15.5% vs 6.6%, 
respectively (p=0.001)). The 1-year mortality rate 
following HF remained higher for RA compared to non-
RA subjects at 35% vs 19.3%, respectively (p=0.01). 
After adjusting for age, sex, and calendar year, RA 
subjects experienced a 2.39-fold higher risk of death 30 
days following onset of HF compared to non-RA 
subjects (HR 2.39, 95% CI 1.36-4.18). At 1 year, this 
mortality difference was similar but less pronounced 
(adjusted HR 2.02, 95% CI 1.40-2.90). After also 
adjusting for use of CV medications and CHD, the 
excess 1-year mortality was similar (HR 1.89, 95% CI 
1.26-2.84). Among those who survived the first year 
after onset of HF, there was no difference in overall 
survival between RA and non-RA subjects with HF in 
the subsequent years [23]. 
RA patients with HF seemed to have less 
aggressive control of HF and CV risk factors. In 
particular, these patients were administered first-line 
medications for HF treatment (ACE-inhibitors and ! -
blockers) less frequently compared to non-RA subjects: 
ACE inhibitors (15% vs 30%) and ! -blockers (10% vs 
23%) [23]. 
SUMMARY 
CV system involvement is an important co-morbidity 
in rheumatic conditions which is accompanied by high 
mortality rates. In particular, HF is best described in RA 
and mostly is manifested by DD. In patients with RA 
the risk of HF is almost 2 times higher than in general 
population, and this risk is not explained entirely by 
traditional CV risk factors.  
Speckle-tracking echocardiography can be useful in 
detecting early myocardial changes in RA-subjects.  
BNP is an important clinical and prognostic marker 
of HF, but there are no final data concerning the 
screening value of BNP in patients with RA and HF. In 
patients with RA the typical clinical manifestations of 
HF differ from that in general population and have 
some features which are not well studied.  
Both prognosis and outcome of RA patients with HF 
are worse than in non-RA subjects. 
Summarizing all these key points it becomes clear, 
that up to date there is no definitely understanding of 
HF features in RA, identification and early detection of 
which will improve the prognosis of these patients via 
early treatment. And there is still a need in further and 
larger studies in this field. 
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